Roche Holding AG (OTCMKTS:RHHBY) Stock Holdings Boosted by Bard Financial Services Inc.

Bard Financial Services Inc. raised its position in shares of Roche Holding AG (OTCMKTS:RHHBY) by 25.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 138,900 shares of the company’s stock after purchasing an additional 28,050 shares during the quarter. Bard Financial Services Inc.’s holdings in Roche were worth $5,716,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. HighPoint Advisor Group LLC boosted its stake in Roche by 2.8% during the 4th quarter. HighPoint Advisor Group LLC now owns 11,091 shares of the company’s stock valued at $387,000 after purchasing an additional 304 shares in the last quarter. Fulton Bank N.A. boosted its stake in Roche by 2.6% during the 1st quarter. Fulton Bank N.A. now owns 12,620 shares of the company’s stock valued at $518,000 after purchasing an additional 314 shares in the last quarter. Confluence Investment Management LLC boosted its stake in Roche by 3.6% during the 1st quarter. Confluence Investment Management LLC now owns 14,491 shares of the company’s stock valued at $596,000 after purchasing an additional 510 shares in the last quarter. Altrius Capital Management Inc boosted its stake in Roche by 0.3% during the 4th quarter. Altrius Capital Management Inc now owns 183,448 shares of the company’s stock valued at $6,399,000 after purchasing an additional 603 shares in the last quarter. Finally, Hancock Whitney Corp boosted its stake in Roche by 6.8% during the 4th quarter. Hancock Whitney Corp now owns 23,516 shares of the company’s stock valued at $820,000 after purchasing an additional 1,496 shares in the last quarter.

Roche Price Performance

OTCMKTS RHHBY opened at $41.07 on Wednesday. Roche Holding AG has a fifty-two week low of $33.34 and a fifty-two week high of $44.31. The stock’s 50-day moving average is $39.19 and its two-hundred day moving average is $38.94. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.97 and a current ratio of 1.26.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Hsbc Global Res lowered Roche from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 28th. HSBC lowered Roche from a “buy” rating to a “hold” rating in a research note on Monday, April 28th. Morgan Stanley initiated coverage on Roche in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. Finally, UBS Group raised Roche from a “hold” rating to a “strong-buy” rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Roche currently has an average rating of “Moderate Buy”.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.